General
publicado em 26/12/2012 às 13h34:00
   Dê o seu voto:

U.S. approves first inhaled treatment for schizophrenia and bipolar disorder

Adasuve passes through the lungs and reach the bloodstream more rapidly than ordinary tablet, new research shows

 
font size
A-
A+

A lexza Pharmaceuticals Inc said the U.S. health regulators approved Adasuve, making it the first treatment for schizophrenia and bipolar disorder that can be inhaled.

Adasuve, which delivers an older antipsychotic drug called loxapine, passes through the lungs and into the bloodstream faster than a typical pill. Loxapine is available as an oral drug for schizophrenia.

The company said the product will include a boxed safety warning about potentially dangerous side effects including the potential for fatal bronchial spasms in people with asthma or chronic obstructive pulmonary disorder and a higher risk of death in elderly people with dementia-related psychosis.

Adasuve use will be restricted to mitigate the potential harm of bronchial spasms, Alexza said.

The FDA also required Alexza to conduct a large post- marketing clinical trial of patients to assess the real-world use of the drug.

"We believe that the ability to deliver medications rapidly and non-invasively will be important for patients and the professionals who care for them," Chief Executive Thomas King said in the statement.

Three injectable drugs, Bristol-Myers Squibb's Abilify, Eli Lilly's Zyprexa and Pfizer Inc's Geodon, are currently approved to calm patients with schizophrenia or bipolar disorder.

Adasuve, Alexza's most advanced drug, will be available for commercial launch early in the third quarter of 2013, the company said.

Earlier this month, European health regulators recommended approval of Adasuve.

The FDA denied approval to Adasuve in May, after it found deficiencies at the company's Mountain View, California manufacturing facility during an inspection.

The company's shares fell 12 percent in the after market trading after the trade was halted at $5.79 before the drug- approval announcement.

Source: Isaude.net
   Palavras-chave:   Inhalation therapy    Schizophrenia    Bipolar disorder    Food and Drug Administration    Adasuve   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: U.S. approves first inhaled treatment for schizophrenia and bipolar disorder
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: U.S. approves first inhaled treatment for schizophrenia and bipolar disorder


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
Inhalation therapy    schizophrenia    bipolar disorder    Food and Drug Administration    Adasuve   
Comments:
Comment
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.